• 中文社会科学引文索引 ( CSSCI ) 来源期刊
  • 中国人文社会科学期刊AMI综合评价 ( A刊 ) 核心期刊
  • 中文核心期刊要目总览核心期刊
  • 中国科技核心期刊 ( 社会科学 )
  • 全国高校社科精品期刊
  • 北京高校人文社会科学名刊
GUO Chaoxian, SHI Bohan. Evaluation of International Competitiveness of China's Pharmaceutical Industry and Countermeasures for High Quality Development During the "14th Five Year Plan" Period[J]. JOURNAL OF BEIJING UNIVERSITY OF TECHNOLOGY(SOCIAL SCIENCES EDITION), 2021, 21(3): 65-79. DOI: 10.12120/bjutskxb202103065
Citation: GUO Chaoxian, SHI Bohan. Evaluation of International Competitiveness of China's Pharmaceutical Industry and Countermeasures for High Quality Development During the "14th Five Year Plan" Period[J]. JOURNAL OF BEIJING UNIVERSITY OF TECHNOLOGY(SOCIAL SCIENCES EDITION), 2021, 21(3): 65-79. DOI: 10.12120/bjutskxb202103065
shu

Evaluation of International Competitiveness of China's Pharmaceutical Industry and Countermeasures for High Quality Development During the "14th Five Year Plan" Period

  • 1.

    Institute of Industrial Economics, Chinese Academy of Social Sciences, Beijing 100006, China

  • 2.

    Department of Industrial Economics, University of Chinese Academy of Social Sciences, Beijing 102488, China

More Information
  • Received Date: January 14, 2021
  • Available Online: August 07, 2022
    Graphical Abstract
    • Abstract

  • This article uses indicators such as International Market Share, Trade Competitiveness Index, and Revealed Comparative Advantage Index to measure the changes in the international competitiveness of China's pharmaceutical industry, and evaluates its international competitiveness through vertical year-to-year comparisons and horizontal comparisons between countries. It further elaborated from the perspective of product segmentation and industrial chain. Overall speaking, the international competitiveness of China's pharmaceutical industry is not strong, and the competitiveness of high-end products such as biopharmaceuticals and high-tech drugs is even weaker, due to their location at the top end of the industrial value chain. However, some APIs and pharmaceutical excipients at the low end of the value chain have stronger competitiveness. Low intensity of innovation input, slow structural adjustment and low degree of acceptance by the international community are the main reasons for the weak international competitiveness of China's pharmaceutical industry. During the 14th Five-Year Plan period, China should further improve the industrial innovation ecosystem, deepen supply-side structural reforms, and actively promote international cooperation to enhance the international competitiveness of the pharmaceutical industry and promote high-quality development.

    • FullText(HTML)
    • References (16)
  • [1]
    李东红, 李钊. 中国医药产业创新发展报告[R]. 北京: 清华大学全球产业研究院, 2016.
    [2]
    陈健, 陈志. 北京生物医药产业全球价值链攀升的障碍与策略[J]. 全球科技经济瞭望, 2019, 34(4): 19-25. https://www.cnki.com.cn/Article/CJFDTOTAL-QQKL201904004.htm
    [3]
    视野金服. 医药产业链财务分析[EB/OL]. (2020-07-02)[2020-07-02]. https://www.seeyii.com/v2/industryChainDetail.html?.
    [4]
    中国产业信息. 2018年全球前20强制药企业研发支出及研发支出占销售额比例情况[EB/OL]. (2019-01-03)[2020-07-10]. https://www.chyxx.com/industry/201901/704301.html.
    [5]
    国家统计局社会科技和文化产业统计局. 中国高技术产业统计年鉴2019[M]. 北京: 中国统计出版社, 2020.
    [6]
    王学恭, 杨杰荣. 中国医药产业转型升级的方向和重点[J]. 中国医药工业杂志, 2019, 50(6): 681-686, 693. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHOU201906016.htm
    [7]
    徐芳萍, 庄倩, 褚淑贞. 中国医药产业转型升级水平与优化路径探析[J]. 中国新药杂志, 2019, 28(14): 1670-1674. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXYZ201914002.htm
    [8]
    Pharmexec Michael Christel. Pharm exec's top 50 companies 2020[EB/OL]. (2020-07-09)[2020-07-10]. https://www.pharmexec.com/view/pharm-execs-top-50-companies-2020.
    [9]
    2020胡润中国百强大健康民营企业: 谁是中国最有价值的大健康领域民营企业[EB/OL]. (2020-03-18)[2020-07-10]. https://news.mbalib.com/story/248845.
    [10]
    佘鲁林, 温再兴. 中国医药工业信息中心. 中国医药产业蓝皮书(2018)[M]. 北京: 社会科学文献出版社, 2018.
    [11]
    2018年度中国医药工业百强榜[EB/OL]. (2019-08-25)[2020-07-10]. https: //www.sohu.com/a/336308823_120047343.
    [12]
    丁一磊. 中国医药产业供给侧结构性改革的对策分析[J]. 中国医药工业杂志, 2019, 50(12): 1509-1513, 1529. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHOU201912024.htm
    [13]
    李霞. 恒瑞医药: 国际化成效甚微, "医药一哥"如何独领风骚[EB/OL]. (2020-07-16)[2020-07-20]. https://www.sohu.com/a/408006051_100053369.
    [14]
    金碚. 关于大健康产业的若干经济学理论问题[J]. 北京工业大学学报(社会科学版), 2019, 19(1): 1-7, 84. doi: 10.12120/bjutskxb20190101
    [15]
    王飞. 美国生物医药产业创新的升级规律及启示[J]. 南京社会科学, 2019(8): 29-35. https://www.cnki.com.cn/Article/CJFDTOTAL-NJSH201908004.htm
    [16]
    新华社. 习近平: 深入学习坚决贯彻党的十九届五中全会精神确保全面建设社会主义现代化国家开好局[EB/OL]. (2021-01-11)[2021-01-12]. http://www.gov.cn/xinwen/2021-01/11/content_5578954.htm.
    • Related Articles

  • Related Articles

    [1]HUI Ning, ZHANG Linyu. Digital Economy Driven and High Quality Development of Cultural Industry[J]. JOURNAL OF BEIJING UNIVERSITY OF TECHNOLOGY(SOCIAL SCIENCES EDITION), 2024, 24(2): 31-47. DOI: 10.12120/bjutskxb202402031
    [2]LIU Lijuan. Regional Differences and High-quality Development Path of County Urbanization[J]. JOURNAL OF BEIJING UNIVERSITY OF TECHNOLOGY(SOCIAL SCIENCES EDITION), 2023, 23(5): 65-76. DOI: 10.12120/bjutskxb202305065
    [3]ZHAO Jianbo. High-quality Development of Digital Economy: Theoretical Logic and Policy Supply[J]. JOURNAL OF BEIJING UNIVERSITY OF TECHNOLOGY(SOCIAL SCIENCES EDITION), 2023, 23(4): 78-92. DOI: 10.12120/bjutskxb202304078
    [4]HU Angang. Year of Finishing Moderately Prosperous Society Construction in All Respects in 2020——Evaluation of China's Economic and Social Development[J]. JOURNAL OF BEIJING UNIVERSITY OF TECHNOLOGY(SOCIAL SCIENCES EDITION), 2021, 21(5): 1-20. DOI: 10.12120/bjutskxb202105001
    [5]GUO Chaoxian, WANG Jiaqi, LIU Haorong. Studies on How New Infrastructure Empowers High-quality Development of China's Economy[J]. JOURNAL OF BEIJING UNIVERSITY OF TECHNOLOGY(SOCIAL SCIENCES EDITION), 2020, 20(6): 13-21. DOI: 10.12120/bjutskxb20200613
    [6]ZHANG Jiangyang, YUAN Xiaoling, WANG Jun. Research on the Reconstruction of Urban Input-Output Index System Under the High-quality Development[J]. JOURNAL OF BEIJING UNIVERSITY OF TECHNOLOGY(SOCIAL SCIENCES EDITION), 2020, 20(5): 58-67. DOI: 10.12120/bjutskxb20200565
    [7]TANG Jing, XIA Jiechang. Construction of High-quality Development Evaluation Index System for Service Trade and Its Implementation Path[J]. JOURNAL OF BEIJING UNIVERSITY OF TECHNOLOGY(SOCIAL SCIENCES EDITION), 2020, 20(5): 47-57. DOI: 10.12120/bjutskxb20200554
    [8]WANG Yubao, LU Yang, WANG Weihua. New Research Progress on the Coordinated Coupling of High-quality Economic Development and Ecological Environmental Protection[J]. JOURNAL OF BEIJING UNIVERSITY OF TECHNOLOGY(SOCIAL SCIENCES EDITION), 2019, 19(5): 84-94. DOI: 10.12120/bjutskxb20190584
    [9]GUO Chaoxian. Integration of Advanced Manufacturing Industry and Modern Service Industry to Promote High Quality Development of Manufacturing Industry[J]. JOURNAL OF BEIJING UNIVERSITY OF TECHNOLOGY(SOCIAL SCIENCES EDITION), 2019, 19(4): 49-60. DOI: 10.12120/bjutskxb20190449
    [10]GUO Chaoxian. Current China's Industrial Development Issues and Its High Quality Development in Future[J]. JOURNAL OF BEIJING UNIVERSITY OF TECHNOLOGY(SOCIAL SCIENCES EDITION), 2019, 19(2): 50-59. DOI: 10.12120/bjutskxb20190250

  • Cited by

    Periodical cited type(21)

    1. 刘海涛. 我国生物医药产业高质量发展的现状、挑战与应对. 经济界. 2025(01): 82-87 .
    2. 楼玉兰，张琳，梁宗锁. 服务区域生物医药产业发展的生物类专业人才培养模式探索. 药学教育. 2025(01): 21-24 .
    3. 孙伟，王申金，刘小溪，张晨阳，王嵘，韩明君，肖扬，阳燕，刘威. 凹凸棒石在生物医学领域中的应用研究进展. 硅酸盐学报. 2024(01): 359-370 .
    4. 王珊珊，倪飞，干行健，孙君. 中国医药制造业发展水平测度及空间差异分析. 卫生软科学. 2024(05): 21-25 .
    5. 王娟，李梦淼. TOE框架下医药制造企业高质量发展组态路径——基于fsQCA 和NCA混合研究方法. 中南民族大学学报(人文社会科学版). 2024(09): 148-160+187-188 .
    6. 孙立，孟海华. 我国生物医药科技成果转化的制约因素分析和战略规划建议. 科技管理研究. 2023(02): 144-150 .
    7. 皮邦游，柏承燚，柏振忠. 鄂西“一州两县”中药材产业竞争力模型构建及实证分析. 南方农业. 2023(01): 174-181 .
    8. 郭朝先，许婷婷. 我国医药产业链供应链韧性和安全水平研究. 经济与管理. 2023(03): 82-93 .
    9. 周胜男，申俊龙，李洁. 基于社会网络理论的生物医药产业集群创新组合模式研究——以江苏省为例. 科技管理研究. 2023(10): 127-135 .
    10. 王冠祎，张赛赛. 基于全球价值链的中国医药制造业国际竞争力和国别依赖评估. 科技和产业. 2023(13): 22-30 .
    11. 陶菁，姚英. 集中带量采购对上海市松江中心医院他汀类药物使用情况的影响. 中国药事. 2023(09): 1060-1073 .
    12. 宋歌. 我国药品专利链接制度的规则透视与路径完善. 黄河科技学院学报. 2023(09): 82-90 .
    13. 沈霞芬，戴维娜，蔡强，吴利芳，姚珏. “大市场-专药品”监管模式对省域医药产业发展的影响与思考. 中国食品药品监管. 2023(07): 114-121 .
    14. 旷南岳，刘晓霞，林娟. 苯磺酸氨氯地平片带量采购对其他钙通道阻滞剂使用情况的影响研究. 中国医院用药评价与分析. 2022(01): 93-96 .
    15. 李海天，李祥. 中国生物医药产业产学研合作模式研究. 科技和产业. 2022(07): 57-62 .
    16. 顾才东. 基于华为引领的国际顶级科产学经产业链构建策略—以苏州市为例. 苏州市职业大学学报. 2022(03): 22-25 .
    17. 华欣，丁健，乔萍. 我国高技术产业国际竞争力脆弱性评价指标体系研究. 国际经济合作. 2021(04): 54-64 .
    18. 陈素梅，史丹. 全球产业链下中国医药业的参与特征:基于产业间关联与产业内贸易的视角. 当代经济管理. 2021(08): 15-23 .
    19. 郑怀国，秦晓婧，齐世杰，贾倩. 我国作物种业国际竞争力评价研究与提升对策. 江苏农业科学. 2021(19): 1-8 .
    20. 汤涵，苗采烈，林凡钰，李宗阳，李彩霞，柳鹏程. 中国医药工业发展现状浅析与未来挑战. 中国医药工业杂志. 2021(11): 1534-1544 .
    21. 崔蓓，王磊. 基于解释结构模型的我国生物医药创新能力影响因素分析. 中国卫生政策研究. 2021(12): 67-73 .

    Other cited types(29)

Catalog

    Get Citation
    PDF
    XML
    Article views PDF downloads Cited by(50)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Editorial office of Journal of Beijing University of Technology(Social Sciences Edition)京公安备11019343018-20001

    Address：No.100 Pingleyuan, Chaoyang District, Beijing 100124,China Tel：010-67396311 E-mail：xuebaosk@bjut.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd. 

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return